Skip directly to content



The mission of the EU 2014 ASPIRE Awards in Vaccine Research is to advance medical knowledge to better understand the burden of pneumococcal disease in children and adults.


The burden of pneumococcal disease in the general population of all ages has been extensively studied; however, it is not well-defined in special populations, including subgroups with underlying disease / medical co morbidities and/or those living in long-term community settings.

Request for Proposals

Pfizer invites investigators to apply for the EU 2014 ASPIRE Awards in Vaccine Research through submission of innovative research proposals for evaluation of the epidemiology and burden of pneumococcal disease in children and adults  with or without  underlying disease/ medical co morbidities and/or those living in long-term community settings.

2014 Research Topic

Evaluating the Burden of Pneumococcal Disease in children and adults in European countries

An applicant should have a strong research interest within the areas of focus and should consider the following components when developing their research proposals:

A. The burden of pneumococcal disease and serotype distribution in children and adults including but not limited to:

  • Individuals with or without increased risk of pneumococcal disease including those with underlying disease/ medical comorbidities.
    Comorbidities may include but are not limited to:
    • Diabetes mellitus
    • Chronic obstructive pulmonary disease (COPD) or other chronic pulmonary disorder
    • Oncologic  disease    
    • Chronic renal disease
    • Hepatic disease
    • Autoimmune disorders
  • Those living in community settings (e.g., extended-care facilities, correctional institutions, nursing homes).
  • Regional evaluation of pneumococcal resistance and serotype distribution.
  • Carriage of Streptococcus pneumoniae in children and  adult populations.

B. Association of pneumococcal pneumonia with influenza or other respiratory viral illnesses

C. The following topics fall outside of the scope of the 2014 EU ASPIRE Vaccine Research Program:

  • General education and / or training.
  • Support for ongoing clinical programs that are part of an organization’s routine operations.
  • Proposals that evaluate populations outside of the defined European countries.
  • Interventional studies where 13 – valent pneumococcal polysaccharide conjugate vaccine is given as an investigational vaccine
  • Proposals whose primary objective is to financially quantify outcomes as it relates to a Pfizer product(s) are outside the scope of the program.

Research Expectations

Within the specified patient populations of interest, investigators are expected to:

  • Generate data regarding the burden of pneumococcal disease in children and  adults and/or evaluation of vaccination practices .
  • Be able to complete the research in 12 months.
  • Present and/or publish the results of the study.

Available Awards

Pfizer is funding research awards up to a maximum of   80 000 Euros each (including direct costs, institutional overhead costs, and indirect costs) for one year to conduct research generating data that will lead to a better understanding of burden of pneumococcal disease in children and adults.

*Please note that study budgets will be evaluated separately to ensure the requested funding is commensurate with the work proposed.

Deadline for Application

Applications must be received by 11:59pm EST on April 9, 2014.

*Eligible countries include: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom.